References
- Fayad L, Kantarjian H, O'Brien S, Seong D, Albitar M, Keating M, et al. Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases. Leukemia 1997; 11: 767–771
- Ohtsuka E, Kikuchi H, Abe Y, Moriyama K, Ohno E, Hirota K, et al. Acute myeloblastic leukaemia without Philadelphia chromosome developing after interferon therapy for chronic myelocytic leukaemia with Philadelphia chromosome. Br J Haematol 1995; 90: 951–953
- Herens C, Baron F, Croisiau C, Tassin F, Bours V. Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases. Cancer Genet Cytogenet 2003; 147: 78–80
- Schoch C, Haferlach T, Kern W, Schnittger S, Berger U, Hehlmann R, et al. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. Leukemia 2003; 17: 461–463
- Chee Y L, Vickers M A, Stevenson D, Holyoake T L, Culligan D J, et al. Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones. Leukemia 2003; 17: 634–635
- Medina J, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 2003; 98: 1905–1911
- O'Dwyer M E, Gatter K M, Loriaux M, Druker B J, Olson S B, Magenis R E, et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 2003; 17: 481–487
- Terre C, Eclache V, Rousselot P, Imbert M, Charrin C, Gervais C, et al. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 2004; 18: 1340–1346
- Cullen M J, Richards S J, Dickinson H, Carter C, Swirsky D M, Owen R G. Development and progression of a Philadelphia-chromosome-negative acute myelocytic leukemia clone in a patient with Philadelphia-chromosome-positive chronic myelocytic leukemia. Cancer Genet Cytogenet 2004; 148: 170–173
- Bacher U, Hochhaus A, Berger U, Hiddemann W, Hehlmann R, Haferlach T, et al. Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha. Leukemia 2005; 19: 460–463
- Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo L V, Cortes J. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 2006; 108: 2811–2813
- Ross D M, Branford S, Moore S, Hughes T P. Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. Leukemia 2006; 20: 664–670
- Lin Y, Bruyere H, Horsman D E, Pantzar T, Barnett M J, Hogge D E, et al. Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors. Cancer Genet Cytogenet 2006; 170: 16–23
- Roy L, Guilhot J, Martineau G, Larchee R, Guilhot F. Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia. Leukemia 2005; 19: 1689–1692
- Thiele J, Kvasnicka H M, Schmitt-Graeff A, Kriener S, Engels K, Staib P, et al. Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patients. Histopathology 2005; 46: 540–550